Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD
NCT05979844Phase 3Completed
- Start
- Oct 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midomafetamine in post-traumatic stress disorder (PTSD). Primary endpoint: Clinician-rated PTSD symptoms. Started Oct 2023; status: completed.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05979844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979844.